📣 Call for Papers We’re inviting submissions for our special collection: Clinical Trials Driving Innovation in Oncology Share your latest research and help shape the future of cancer care. 🔗 Learn more & submit: buff.ly/bioqZyF #Oncology #ClinicalTrials #AcademicPublishing #CallForPapers

📰 Do antibody–drug conjugates outperform docetaxel in previously treated advanced NSCLC? This systematic review & meta-analysis of RCTs explores efficacy and safety outcomes 👇 🔗 buff.ly/YzcZqhm #Oncology #LungCancer #NSCLC #CancerResearch #ClinicalTrials

🧪 Can a simple blood-based marker help predict treatment response in ESCC? This multicenter real-world study evaluates PIV in patients receiving neoadjuvant chemotherapy combined with anti–PD-1 therapy. 🔗 buff.ly/XjR59n1 #Oncology #Biomarkers #Immunotherapy

📘 Evidence for post-progression strategies in HER2+ metastatic #BreastCancer with brain metastases remains limited. This multicenter real-world study adds insight into pyrotinib treatment beyond progression and rechallenge: buff.ly/0sbfEcd #ClinicalResearch

🆕 Can genotype-guided dosing improve outcomes in metastatic #colorectalcancer? This phase II RCT explores regorafenib + FOLFIRI with UGT1A1-guided irinotecan escalation👇 🔗 journals.sagepub.com/doi/full/10.... #Oncology #ClinicalTrials #PrecisionMedicine

📢Can a simple blood-based marker predict outcomes to #immunotherapy? This study explores how the pretreatment NLR relates to immune checkpoint inhibitor response in advanced #NSCLC with liver metastases. 🔗 Read more: buff.ly/osVDOYL #LungCancer #CancerResearch #Biomarkers

Cytokine release syndrome (CRS) isn’t just a challenge in hematologic cancers -it’s increasingly relevant in solid tumours. This review dives into mechanism-driven strategies for prevention and management. 📖 buff.ly/ZDar0oT #Oncology #Immunotherapy #CancerResearch #ClinicalInsights

🧬 Review on Solitary Fibrous Tumour explores histology, behaviour, risk assessment & treatment strategies. Stay ahead with the latest insights 👇 🔗 buff.ly/Yzeri1f #Oncology #Pathology #CancerResearch

📊 IF 4.1 for Therapeutic Advances in Medical Oncology 🎉 Consistent, high-quality research in oncology - 📚 Start reading: journals.sagepub.com/home/tam #ImpactFactor #OncologyResearch

🔬Research shows how virtual multiplex immunofluorescence can identify lymphocyte subsets that predict response to neoadjuvant therapy - advancing precision oncology. Read more: buff.ly/PvVYaEX #Oncology #CancerResearch #Immunology #PrecisionMedicine

📣 Call for Papers – Submit to our Special Collection on: Tumor Microenvironment in GI Cancers 🔬 Focus: clinically actionable biomarkers & therapeutic insights 📊 Clinical + translational research encouraged 🗓 Deadline: 15 March 2027 👉 buff.ly/dpUqDMk #CallForPapers #PrecisionOncology

🆕 Nationwide real‑world data reveal how treatment gaps are linked to survival outcomes in #HepatocellularCarcinoma, highlighting unmet needs in routine care. 🔗 buff.ly/BF3QeGz #HCC #LiverCancer #CancerOutcomes #RealWorldEvidence

How do physicians approach treatment decisions for young patients with HR+, HER2‑ early #breastcancer? This Latin American survey provides insights into real‑world clinical practice. 🔗 buff.ly/isnY3xJ #BreastCancer #YoungPatients #ClinicalPractice #Oncology

🆕 This study explores afatinib dose optimization to improve outcomes while reducing toxicities in advanced EGFR‑mutated NSCLC patients in Vietnam. 🔗 buff.ly/XucLdR2 #LungCancer #NSCLC #EGFR #TargetedTherapy #Oncology

📢 This phase Ib/II study investigates the addition of neoadjuvant neratinib to standard therapy in patients with inflammatory #breastcancer, including those with HER2+ and HR+/HER2‑ disease across stage III and IV settings. 👉 Read the full article: buff.ly/bFwUuVM #InflammatoryBreastCancer #HER2 #

🆕 A multicenter phase II randomized trial evaluates Endostar + concurrent chemoradiotherapy in locally advanced cervical cancer. 🔗 Read the full article: buff.ly/mQhOTsg #CervicalCancer #OncologyResearch #ClinicalTrials #Radiotherapy

🚨 Call for Papers The KRAS era is here - now we need strategies to anticipate & overcome resistance in pancreatic cancer. Submit by Mar 1, 2027: KRAS pathways, combos, resistance mechanisms, new targets & models. 🔗 buff.ly/eMwzb2N #PDAC #KRAS #TargetedTherapy #CancerResearch

A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection. buff.ly/6PIVm3G #Cholangiocarcinoma #GeriatricOncology

📣 Call for Papers A Collection in Ther Adv Med Oncol focuses on #ADCs in gynecologic cancers, including ovarian, endometrial, and cervical malignancies. We welcome clinically relevant research and reviews. 🗓️ Deadline: 26 Feb 2027 buff.ly/30K8r13 #GynecologicOncology #CancerResearch #OpenCall

A narrative review summarises recent advances and key trials of radionuclide therapies, including ²²³Ra, ¹⁷⁷Lu‑labelled agents, and emerging α‑emitters, in metastatic castration‑resistant #ProstateCancer. Ther Adv Med Oncol buff.ly/XQWUg2J #RadionuclideTherapy

We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.” Submission deadline: 19 Feb 2027 buff.ly/xsqkygl #AML #PrecisionOncology #HematologicMalignancies #MRD

A study across Brazil, Mexico, and Peru examines how fertility concerns influence acceptance of (neo)adjuvant chemotherapy among young women with early-stage #BreastCancer, highlighting gaps in awareness and access to fertility preservation. buff.ly/W1gWits #OncoFertility #CancerCare #LatinAmerica

📣 If you will be at #ESTRO26 please connect with my team member Applonia! She is alsI Editor of the journal Technology in Cancer Research & Treatment which has a significant focus on radiation oncology research. #oncosky #oncology #radiotherapy #ESTRO2026

📣 Call for Papers - Volume 2 Following the success of Volume 1, Ther Adv Med Oncol launches Volume 2 of this Collection on #ADC in #BreastCancer, focusing on new standards, emerging challenges, and future directions. Deadline: 29 Jan 2027 journals.sagepub.com/topic/collec... #MedicalOncology

Resistance to second‑generation AR pathway inhibitors remains a key challenge in #ProstateCancer. This review explores mechanisms of resistance and emerging third‑generation strategies, including AR degraders and steroid biosynthesis inhibitors. buff.ly/dDwk7Tz #AndrogenReceptor #PrecisionOncology

Call for papers: a new collection in Ther Adv Med Oncol focuses on immunotherapy for T‑cell malignancies, spanning checkpoint inhibition, ADCs, bispecifics, cellular therapies, biomarkers, and resistance mechanisms. buff.ly/y2kbSVy #HematologicMalignancies #Immunotherapy #TCellLymphoma

Genomic profiling is reshaping research strategies in cervical, vulvar & vaginal cancers. This review summarises molecular features across tumour types and examines emerging targeted and combination approaches, including #ADC. buff.ly/EP7cYS5 #GynOnc #PrecisionOncology #CancerGenomics

A new Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are shaping lung cancer care across the disease continuum. Deadline: 29 Jan 2027 buff.ly/RrkerAu #LungCancer #PrecisionOncology #Biomarkers #MedicalOncology

#ADCs are reshaping breast oncology, alongside new questions on sequencing, biomarkers, and toxicity management. Explore this Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD. buff.ly/pZycpW5 #BreastCancer #ADCs #MedicalOncology #OncologyResearch

A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need. Submission deadline: 14 Dec 2026 buff.ly/Da8ENXI #HRpositive #HER2negative #MedicalOncology

A real‑world retrospective study in Ther Adv Med Oncol examined the prevalence of HER2‑ultralow disease in HR+/HER2‑negative metastatic breast cancer and reported comparable first‑line chemotherapy outcomes to HER2‑low disease. buff.ly/Q7JaadR #BreastCancer #HER2 #MedicalOncology #RealWorldEvidence

Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma. We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes. buff.ly/8jRyYqj #Glioblastoma #NeuroOncology #MedicalOncology

A dual‑center study in Ther Adv Med Oncol evaluated the Systemic Inflammation‑Nutrition Index (SINI) as a predictor of pathological response and relapse‑free survival in locally advanced #GIST treated with neoadjuvant imatinib. buff.ly/fKecUtx #Sarcoma #MedicalOncology #TargetedTherapy

Ther Adv Med Oncol announces an open call for a Special Collection on Modern Approaches to Patient Selection in Breast Cancer. Submissions addressing biomarkers, computational tools, and integrated clinical strategies are welcome. buff.ly/t6TEH5G #BreastCancer #MedicalOncology #PrecisionOncology

A dual‑center study evaluates the systemic inflammation–nutrition index (SINI) as a predictor of pathological response and prognosis in locally advanced #GIST treated with neoadjuvant imatinib. A SINI‑based nomogram showed strong discrimination. buff.ly/pvg142X #Sarcoma #Imatinib #Biomarkers

🚨 Call for Papers! Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open. 🗓 Deadline: 6 Nov 2026 🔗 Submit here: buff.ly/sQgaDWS #Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

Ther Adv Med Oncol: Second‑line mFOLFIRINOX outperformed SOX after gemcitabine+nab‑paclitaxel failure in advanced PDAC (n=113): • OS 10.4 vs 6.1 mo • PFS 4.8 vs 2.4 mo But with higher grade ≥3 AEs. 🔗https://buff.ly/QwPfnx9 #PancreaticCancer #GIOnc

🚨 Call for Papers! Ther Adv Med Onc invites submissions to our Special Collection on combined immunotherapy for advanced HCC. 🗓 Deadline: 30 Oct 2026 🔗 Submit: buff.ly/e8XA6kU #HCC #LiverCancer #Immunotherapy #Oncology

Ther Adv Med Oncol: A review highlights maintenance therapy as a strategy to extend benefit after first‑line anthracyclines in advanced soft tissue #sarcoma. PLD emerges as a promising continuation option with reduced cardiotoxicity. Read: 【🔗https://buff.ly/tV2uyCE 】 #STS #Oncology

📣 Call for Papers Novel Approaches to High‑Risk HER2+ Early‑Stage Breast Cancer - a new Special Collection in Therapeutic Advances in Medical Oncology - is now open. 🗓 Deadline: 4 Dec 2026 🔗 buff.ly/3jv7zmw

A large retrospective cohort shows CLDN18.2 expression does not influence outcomes of first‑line immunochemotherapy in HER2‑negative, pMMR, PD‑L1 CPS≥1 metastatic gastric/GEJ cancer. 🔗 buff.ly/rdAewUh #GastricCancer #Immunotherapy #CLDN182 #Biomarkers

🚨 Call for Papers – Special Collection: Precision Immuno‑Oncology We welcome original research, clinical trials, reviews, and real‑world evidence shaping precision cancer care. Guest Editor: Dr. Peng Luo 🔗 Submission details: buff.ly/fqWNKby #ImmunoOncology #PrecisionMedicine #Biomarkers

A rev in Ther Adv Med Onc highlights the unique challenges of early breast cancer in young BRCA carriers-covering surveillance, risk‑reducing surgery, PARP‑based therapy, fertility considerations, and survivorship needs. 🔗https://buff.ly/6fj4pvT #BreastCancer #BRCA #Oncology #YoungPatients

A review in Ther Adv Med Onc summarizes major advances in SCLC: chemo‑IO as standard in ES‑SCLC, durvalumab approved for LS‑SCLC, emerging options for relapse (lurbinectedin, tarlatamab), and evolving biomarkers/transcriptional subtypes. 🔗https://buff.ly/LoHtjYT #SCLC #LungCancer #Immunotherapy

Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://buff.ly/dOq2XvY #PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need. 🔗 Full article: buff.ly/9fa08rG #ProstateCancer #mCRPC #PARPInhibitors #Oncology

ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC. 🔗https://buff.ly/S2kBuFe #GastricCancer #HER2 #ctDNA

Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients. 🔗 buff.ly/Ckygpuz #Lenvatinib

Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents. 🔗 buff.ly/ZDZelh2 #BreastCancer #YWBC

Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options. 🔗 buff.ly/jJq7xOQ #NSCLC #LungCancer #Oncology #TargetedTherapy